SCHEMBL4514910

SCHEMBL4514910

N=C(NN)c1ccncc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 2/20 0.56
CYP2C19 P33261 2/20 0.56
KDM4E B2RXH2 2/20 0.56
MPO P05164 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
CYP2A6 P11509 1/20 0.56
ALDH1A1 P00352 4/20 0.43
NAPRT Q6XQN6 1/20 0.41
GAA P10253 1/20 0.39
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
PLOD2 O00469 1/20 0.38
PLOD3 O60568 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
PLOD1 Q02809 1/20 0.38
HIF1A Q16665 1/20 0.38
MEN1 O00255 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2849627 0.82 MPO (0.39) CYP3A4CYP2C19KDM4EMPOALDH1A1
SCHEMBL282988 0.78 ALDH1A1 (0.44) CYP2D6CYP1A2CYP3A4CYP2C19KDM4E
Isonicotinic Acid SCHEMBL28953803 0.78 NAPRT (0.49) CYP2D6CYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL16791675 0.77 CYP2D6 (0.42) CYP2D6CYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL8272442 0.76 ALDH1A1 (0.43) CYP2D6CYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL3557897 0.75 F2 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL13108737 0.75 WDR5 (0.44) CYP3A4KDM4EMPOALDH1A1HPGD
Hydrochloric Acid SCHEMBL27786828 0.74 ALDH1A1 (0.41) CYP2D6CYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL4921939 0.74 F7 (0.52) CYP1A2CYP3A4ALDH1A1GAAPLOD2
Hydrochloric Acid SCHEMBL3557093 0.73 BLM (0.54) CYP2D6CYP1A2CYP3A4CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023049438-A1 GRK2 INHIBITORS AND USES THEREOF SONATA THERAPEUTICS, INC. (US) 2023-03-30 WO disclosed
US-8207147-B2 Heterocyclic derivatives as GPCR receptor agonists PROSIDION LIMITED (GB) 2012-06-26 US disclosed
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20080096894-A1 Anti-Bacterial Compounds ASTON UNIVERSITY (GB) 2008-04-24 US disclosed
EP-1845779-A1 ANTI-BACTERIAL COMPOUNDS Aston University (GB) 2007-10-24 EP disclosed
US-20070129371-A1 Novel ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-06-07 US disclosed
WO-2006111716-A1 HETEROARYL DERIVATIVES HAVING ANTI-MYCOBACTERIAL ACTIVITY ASTON UNIVERSITY (GB) 2006-10-26 WO disclosed
WO-2006075159-A1 ANTI-BACTERIAL COMPOUNDS ASTON UNIVERSITY (GB) 2006-07-20 WO disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129371-A1 Novel ethylenediamine derivatives C1R, C9, C1S CYP2D6 1232/4885CYP1A2 3302/4885CYP3A4 1865/4885
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS GPR119, GCGR, GLP1R CYP2D6 1397/4885CYP1A2 873/4885CYP3A4 1365/4885
US-20080096894-A1 Anti-Bacterial Compounds MRPL21, PGLS, FOSB CYP2D6 2324/4885CYP1A2 3458/4885CYP3A4 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.